Core Viewpoint - Dynavax Technologies is set to be acquired by Sanofi for $15.50 per share, valuing the company at approximately $2.2 billion, representing a 39% premium over its previous closing stock price [3]. Group 1: Acquisition Details - Sanofi will initiate a tender offer to purchase Dynavax's stock at $15.50 per share in cash [3]. - The acquisition deal is expected to close in the first quarter of 2026 [3]. Group 2: Market Reaction - Following the announcement, Dynavax's stock price surged by over 38%, reaching $15.38 [1][4]. - The market capitalization of Dynavax is currently around $1.3 billion [4]. Group 3: Product Synergies - The merger will combine Dynavax's adult hepatitis B vaccine and shingles vaccine candidate with Sanofi's extensive global scale and commercial distribution network [6]. - Dynavax's adult hepatitis B vaccine offers a two-dose regimen that provides protection more quickly than traditional three-dose vaccines [7]. - The shingles vaccine candidate from Dynavax is in early clinical development, targeting protection against a viral disease that can cause severe pain [8].

Group 1 - European markets are expected to open flat to negative as investors assess a volatile year during the Christmas Eve trading session [1] - The pan-European Stoxx 600 closed 0.3% higher, reaching a new record closing high, driven by Novo Nordisk's share price surge after FDA approval for the first GLP-1 pill [2] - Sanofi announced the acquisition of Dynavax for $2.2 billion, which has a marketed adult hepatitis B vaccine and a shingles vaccine candidate [2] Group 2 - Gold and silver futures reached new highs, trading at $4,514.3 per ounce and $72.165 per ounce, respectively [3] - Asia-Pacific markets mostly traded higher, with several indexes closing early for the Christmas Eve holiday [6]